Ascentage

finance numbers tape money
Biotech

Obesity biotech Aardvark eyes IPO as Ascentage makes $126M debut

Aardvark’s pipeline is headed up by ARD-101, a bitter taste receptor pan-agonist designed to stimulate enteroendocrine cells of the digestive tract.
James Waldron Jan 24, 2025 5:02am
IPO initial public offering

BMS, Takeda's Chinese partners file for IPOs

Jan 22, 2025 6:11am